News and Events
23 April 2012
Results announcement for the six months ended 31 January 2012
£25 million invested to commercialise opportunities from UK's four leading research universities year to date & £109.5 million funds available
Imperial Innovations Group plc (AIM: IVO, "Innovations", "the Group"), a leading technology commercialisation and investment group, has published its results for the six months ended 31 January 2012.
Innovations leads £3m funding round in Abingdon Health
26 March 2012
Imperial Innovations Group plc (AIM: IVO, ‘Innovations’), a leading technology commercialisation and investment group, has led a £3m funding round in Abingdon Health, a specialist medical diagnostics company, alongside other private investors.
Professor David Begg joins as non-executive director
21 March 2012
Imperial Innovations (AIM: IVO, "Imperial Innovations"), a leading technology commercialisation and investment company, announces that Professor David Begg has joined the Board as a non-executive director with immediate effect.
Circassia ragweed vaccine achieves phase II clinical development milestone
08 March 2012
Imperial Innovations Group plc (AIM: IVO, ‘Innovations’, or ‘the Group’), a leading technology commercialisation and investment company, announces that portfolio company Circassia has successfully completed a large-scale phase II clinical study of its ToleroMune® ragweed allergy treatment.
